Filtered By:
Condition: Kidney Transplantation

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 40016 results found since Jan 2013.

Attenuating Ischemia-Reperfusion Injury in Kidney Transplantation by Perfusing Donor Organs With siRNA Cocktail Solution
Conclusions: In conclusion, this is the first demonstration that perfusing donor organs with an siRNA cocktail solution can induce gene silencing in the kidney and prevent kidneys from extended cold I/R injury in kidney transplantation, highlighting the promise of the clinical application of siRNA-based therapies in the preservation of donor organs.
Source: Transplantation - March 22, 2016 Category: Transplant Surgery Tags: Original Basic Science-General Source Type: research

Innate immunity activation involved in unprotected porcine auto-transplant kidneys preserved by naked caspase-3 siRNA
Conclusions: The activation of innate immunity with amplified inflammatory responses in the caspase-3 siRNA preserved auto-transplant kidneys are associated with increased TLR3, TLR7 and PKR, which might be due to complementary systemic feedback, although persistent actions initiated by short-acting caspase-3 siRNA cannot be completely ruled out. These results provided valuable evidence to guide future siRNA design and pre-clinic studies.
Source: Journal of Translational Medicine - September 13, 2013 Category: Research Authors: Cheng YangLong LiYinjia XueZitong ZhaoTian ZhaoYichen JiaRuiming RongMing XuMichael NicholsonTongyu ZhuBin Yang Source Type: research

siRNA Technology in Kidney Transplantation: Current Status and Future Potential
Abstract Kidney transplantation is one of the most common transplantation operations in the world, accounting for up to 50 % of all transplantation surgeries. To curtail the damage to transplanted organs that is caused by ischemia–reperfusion injury and the recipient’s immune system, small interfering RNA (siRNA) technology is being explored. Importantly, the kidney as a whole is a preferential site for non-specific systemic delivery of siRNA. To date, most attempts at siRNA-based therapy for transplantation-related conditions have remained at the in vitro stage, with only a few of them being advanced into a...
Source: BioDrugs - August 1, 2014 Category: Drugs & Pharmacology Source Type: research

Prostaglandins for adult liver transplanted recipients
CONCLUSIONS: Eleven trials evaluated prostaglandins in adult liver transplanted recipients. Based on low-certainty evidence, prostaglandins may reduce all-cause mortality up to one month; may cause little to no difference in serious adverse events, liver retransplantation, early allograft dysfunction, primary non-function of the allograft, and length of hospital stay; and may have a large reduction in the development of acute kidney injury requiring dialysis. We do not know the effect of prostaglandins on adverse events considered non-serious. We lack adequately powered, high-quality trials evaluating the effects of prosta...
Source: Cochrane Database of Systematic Reviews - August 4, 2023 Category: General Medicine Authors: Zubair Umer Mohamed Christi Titus Varghese Abish Sudhakar Lakshmi Kumar Unnikrishnan Gopalakrishnan Dinesh Balakrishnan Ramachandran Narayanamenon Surendran Sudhindran Source Type: research

Antibody induction therapy for lung transplant recipients.
CONCLUSIONS: No clear benefits or harms associated with the use of T-cell antibody induction compared with no induction, or when different types of T-cell antibodies were compared were identified in this review. Few studies were identified that investigated use of antibodies against T-cells for induction after lung transplantation, and numbers of participants and outcomes were also limited. Assessment of the included studies found that all were at high risk of methodological bias.Further RCTs are needed to perform robust assessment of the benefits and harms of T-cell antibody induction for lung transplant recipients. Futur...
Source: Cochrane Database of Systematic Reviews - November 27, 2013 Category: Journals (General) Authors: Penninga L, Møller CH, Penninga EI, Iversen M, Gluud C, Steinbrüchel DA Tags: Cochrane Database Syst Rev Source Type: research

Darbepoetin for the anaemia of chronic kidney disease.
CONCLUSIONS: Data suggest that darbepoetin alfa effectively reduces need for blood transfusions in adults with CKD stage 3 to 5, but has little or no effect on mortality or quality of life. The effects of darbepoetin alfa in adults with CKD stage 5D and kidney transplant recipients and children with CKD remain uncertain as do the relative benefits and harms of darbepoetin alfa compared with other ESAs (epoetin alfa or beta and methoxy polyethylene glycol-epoetin beta). PMID: 24683046 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - March 31, 2014 Category: Journals (General) Authors: Palmer SC, Saglimbene V, Craig JC, Navaneethan SD, Strippoli GF Tags: Cochrane Database Syst Rev Source Type: research

Interventions for lowering plasma homocysteine levels in kidney transplant recipients.
CONCLUSIONS: There is no current evidence to support the use of homocysteine lowering therapy for cardiovascular disease prevention in kidney transplant recipients. PMID: 25938479 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - May 4, 2015 Category: Journals (General) Authors: Kang A, Nigwekar SU, Perkovic V, Kulshrestha S, Zoungas S, Navaneethan SD, Cass A, Gallagher MP, Ninomiya T, Strippoli GF, Jardine MJ Tags: Cochrane Database Syst Rev Source Type: research

Urinary alkalisation for symptomatic uncomplicated urinary tract infection in women.
CONCLUSIONS: Until relevant evidence is generated from randomised trials, the safety and efficacy of urinary alkalisers for the symptomatic treatment of uncomplicated UTI remains unknown. PMID: 27090883 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - April 18, 2016 Category: Journals (General) Authors: O'Kane DB, Dave SK, Gore N, Patel F, Hoffmann TC, Trill JL, Del Mar CB Tags: Cochrane Database Syst Rev Source Type: research

Routine intraoperative ureteric stenting for kidney transplant recipients.
CONCLUSIONS: Routine prophylactic stenting reduces the incidence of MUCs. Studies comparing selective stenting and universal prophylactic stenting, whilst difficult to design and analyse, would address the unresolved quality of life and economic issues. PMID: 23771708 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - June 17, 2013 Category: Journals (General) Authors: Wilson CH, Rix DA, Manas DM Tags: Cochrane Database Syst Rev Source Type: research

HMG CoA reductase inhibitors (statins) for kidney transplant recipients.
CONCLUSIONS: Statins may reduce cardiovascular events in kidney transplant recipients, although treatment effects are imprecise. Statin treatment has uncertain effects on overall mortality, stroke, kidney function, and toxicity outcomes in kidney transplant recipients. Additional studies would improve our confidence in the treatment benefits and harms of statins on cardiovascular events in this clinical setting. PMID: 24470059 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - February 3, 2014 Category: Journals (General) Authors: Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegbrant J, Strippoli GF Tags: Cochrane Database Syst Rev Source Type: research

High-performance information search filters for acute kidney injury content in PubMed, Ovid Medline and Embase
Conclusions PubMed, Ovid Medline and Embase can be filtered for articles relevant to AKI in a reliable manner. These high-performance information filters are now available online and can be used to better identify AKI content in large bibliographic databases.
Source: Nephrology Dialysis Transplantation - March 27, 2014 Category: Urology & Nephrology Authors: Hildebrand, A. M., Iansavichus, A. V., Haynes, R. B., Wilczynski, N. L., Mehta, R. L., Parikh, C. R., Garg, A. X. Tags: Acute Kidney Injury Source Type: research

Belatacept for kidney transplant recipients.
CONCLUSIONS: There is no evidence of any difference in the effectiveness of belatacept and CNI in preventing acute rejection, graft loss and death, but treatment with belatacept is associated with less chronic kidney scarring and better kidney transplant function. Treatment with belatacept is also associated with better blood pressure and lipid profile and a lower incidence of diabetes versus treatment with a CNI. Important side effects (particularly PTLD) remain poorly reported and so the relative benefits and harms of using belatacept remain unclear. Whether short-term advantages of treatment with belatacept are maintain...
Source: Cochrane Database of Systematic Reviews - November 24, 2014 Category: Journals (General) Authors: Masson P, Henderson L, Chapman JR, Craig JC, Webster AC Tags: Cochrane Database Syst Rev Source Type: research

Chinese herbal medicine for treating recurrent urinary tract infections in women.
CONCLUSIONS: Evidence from seven small studies suggested that CHM as an independent intervention or in conjunction with antibiotics may be beneficial for treating recurrent UTIs during the acute phase of infection and may reduce the recurrent UTI incidence for at least six months post-treatment. CHM treatments specifically formulated for recurrent UTI may be more effective than herbal treatments designed to treat acute UTI. However, the small number and poor quality of the included studies meant that it was not possible to formulate robust conclusions on the use of CHM for recurrent UTI in women either alone or as an adjun...
Source: Cochrane Database of Systematic Reviews - June 4, 2015 Category: Journals (General) Authors: Flower A, Wang LQ, Lewith G, Liu JP, Li Q Tags: Cochrane Database Syst Rev Source Type: research

Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP).
CONCLUSIONS: There are no substantial changes in conclusions from this update compared with the initial review. From generally low quality evidence, we found no evidence of benefit from RCTs for the use of prednisone or antiplatelet agents to prevent persistent kidney disease in children with HSP. Though heparin appeared effective, this potentially dangerous therapy is not justified to prevent serious kidney disease when fewer than 2% of children with HSP develop severe kidney disease. No evidence of benefit has been found for cyclophosphamide treatment in children or adults with HSP and severe kidney disease. Because of s...
Source: Cochrane Database of Systematic Reviews - August 7, 2015 Category: Journals (General) Authors: Hahn D, Hodson EM, Willis NS, Craig JC Tags: Cochrane Database Syst Rev Source Type: research